Actively Recruiting
Phase 1 Study of SG1906 for Patients With CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Led by Hangzhou Sumgen Biotech Co., Ltd. · Updated on 2026-08-11
60
Participants Needed
9
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety, tolerability, pharmacokinetics, and early effectiveness of SG1906 in patients with CLDN18.2-positive locally advanced unresectable or metastatic solid tumors. It is a Phase IaIb clinical trial focusing on patients who have relapsed after, failed, or are intolerant to standard therapies. The trial includes patients with specific types of solid tumors, including gastricgastroesophageal junction adenocarcinoma and pancreatic cancer. Patients will receive SG1906 through intravenous infusion every two weeks. Phase Ia involves dose escalation using seven dose levels from 0.1 mgkg to 12 mgkg to find the recommended dose. Phase Ib expands treatment to more patients with confirmed CLDN18.2-positive tumors. Treatment continues until disease progression, intolerable side effects, new anticancer therapy, consent withdrawal, loss to follow-up, death, or study end. Participants will be closely monitored with tumor tissue testing for CLDN18.2, evaluations of organ function, and assessments of adverse events and drug levels. Researchers will measure safety outcomes such as treatment-related adverse events and maximum tolerated dose, as well as pharmacokinetics and immunogenicity over about one year. The study will also evaluate preliminary efficacy and receptor occupancy throughout the study duration.
CONDITIONS
Brief Title
SG1906 for CLDN18.2-Positive Solid Tumors
Research Team
P
Pengyu Shi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here